SGLT2 Inhibitors Provide Broad Cardiovascular and Cardiorenal Protection Beyond Glycemic Control via Multi-layered Mechanisms

While initially developed as glucose-lowering agents for type 2 diabetes mellitus, Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors have demonstrated significant cardiovascular and cardiorenal benefits that extend beyond glycemic control. The precise mechanisms underlying this profound cardioprotection, particularly in conditions like heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF), are not fully understood. Current standard-of-care often focuses on symptom management and risk factor modification, but SGLT2 inhibitors offer a novel approach to directly improve cardiac outcomes, necessitating a comprehensive understanding of their multi-faceted actions.

This integrative narrative review synthesized current mechanistic and clinical evidence regarding SGLT2 inhibitors in cardiovascular disease. The authors proposed a translational framework linking various physiological effects to their observed benefits. The review specifically summarized data for empagliflozin and dapagliflozin, analyzing their impact across different cardiovascular conditions, including heart failure, ischemic heart disease, post-myocardial infarction remodeling, and arrhythmias. It also incorporated safety considerations to provide a holistic view of their clinical utility.

The review confirmed robust prognostic benefits for empagliflozin and dapagliflozin in heart failure with reduced ejection fraction (HFrEF) and expanding therapeutic value in heart failure with preserved ejection fraction (HFpEF). These benefits are not solely explained by glucose lowering, but rather by a multilayered network of systemic, metabolic, vascular, and cellular mechanisms.

Cardiovascular protection by SGLT2 inhibitors is mediated through hemodynamic rebalancing, cardiometabolic reprogramming, vascular protection, redox homeostasis, mitochondrial quality control, immunometabolic modulation, and attenuation of adverse myocardial remodeling. In post-myocardial infarction settings, SGLT2 inhibitors may improve N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels and ventricular remodeling parameters, although effects on hard clinical endpoints remain inconsistent. Emerging evidence suggests a potential reduction in atrial fibrillation or flutter risk, but dedicated trials are required to confirm these findings. Safety considerations, including genital infections, volume depletion, renal function changes, and euglycemic ketoacidosis, were also highlighted.